Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression-Reference-Cited by-同舟云学术

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression

Published:2009-07-14 Issue:3 Volume:101 Page:432-440
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Chen H,Hao J,Wang L,Li Y

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605185.pdf

Reference38 articles.

1. Afify AM, Craig S, Paulino AF (2006) Temporal variation in the distribution of hyaluronic acid, CD44s, and CD44v6 in the human endometrium across the menstrual cycle. Appl Immunohisto M M 14: 328–333

2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22

3. Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Melendez-Alafort L, Mazzi U, Zanovello P, Rosato A (2008) A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 14: 3598–3606

4. Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000) Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma: diagnostic and prognostic implications. Clin Exp Metastasis 18: 197–202

5. Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brunner N, Jones TR, Silverman MH, Gold MA (2005) A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 99: 50–57

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomaterial considerations for ovarian cancer models;Frontiers in Materials;2023-08-03

2. Repurposing of the Drug Tezosentan for Cancer Therapy;Current Issues in Molecular Biology;2023-06-11

3. Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives;Cancer Letters;2023-03

4. Targeting ovarian cancer stem cells: a new way out;Stem Cell Research & Therapy;2023-02-14

5. Potential Drug Targets for Ovarian Cancer Identified Through Mendelian Randomization and Colocalization Analysis;2023